Cytokinetics announces positive Phase 3 SEQUOIA-HCM results for aficamten in obstructive HCM

CYTOKINETICS INC

Aficamten improved exercise capacity (pVO2) vs placebo: LS mean diff 1.74 mL/kg/min (p=0.000002).
All 10 prespecified secondary endpoints met with statistical significance (p<0.0001), including KCCQ-CSS and NYHA class.
Safety profile comparable to placebo; SAEs 5.6% aficamten vs 9.3% placebo; LVEF <50% in 3.5% vs 0.7%.
No worsening heart failure or treatment interruptions due to low LVEF; full results at upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.